FDA decision will enable Iksuda to expand its ongoing clinical trial in the US, Australia and Singapore Preliminary data from an ongoing dose-escalation study of IKS014 has shown meaningful clinical ...

Daiichi and AZ have estimated that approximately 60% to 65% of HR-positive, HER2-negative breast cancers are HER2-low and potentially an additional 25% may be HER2-ultra-low.

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

Our findings highlight the molecular diversity and diagnostic challenges of HER2-mutated NSCLC in underrepresented ...

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

A prognostic index can be used to identify patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer who can safely forgo adjuvant chemotherapy as well as patients who require ...

One word: slay.

cancer with FGFR2b overexpression and who are non-HER2 positive. FGFR2b overexpression was defined as 2+/3+ staining in ≥10% of tumor cells by centrally performed immunohistochemistry (IHC) testing.

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab with chemotherapy, achieved ...

ORLANDO, FLORIDA / ACCESS Newswire / June 27, 2025 / RedChip Companies will air an interview with Greenwich LifeSciences, Inc ...

Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Learn ...

Back in 2021, Amgen picked up the phase 3-ready candidate in a $1.9 billion acquisition of Five Prime Therapeutics. The ...